Prognostic value of an inflammation-based score in patients undergoing pre-operative chemotherapy followed by surgery for esophageal cancer

Miyata,Hiroshi; Yamasaki,Makoto; Kurokawa,Yukinori; Takiguchi,Shuji; Nakajima,Kiyokazu; Fujiwara,Yoshiyuki; Mori,Masaki; Doki,Yuichiro

doi:10.3892/etm.2011.308

Prognostic value of an inflammation-based score in patients undergoing pre-operative chemotherapy followed by surgery for esophageal cancer

Authors:
- Hiroshi Miyata
- Makoto Yamasaki
- Yukinori Kurokawa
- Shuji Takiguchi
- Kiyokazu Nakajima
- Yoshiyuki Fujiwara
- Masaki Mori
- Yuichiro Doki
View Affiliations

Affiliations: Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan
Published online on: June 30, 2011 https://doi.org/10.3892/etm.2011.308
Pages: 879-885

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recent studies have shown that the presence of systemic inflammation is associated with poor outcome in patients with malignancy. However, whether systemic inflammation affects the response to pre-operative therapy and survival of patients undergoing multimodal treatment for esophageal cancer is not clear. We studied 152 patients who underwent pre-operative chemotherapy followed by surgery for esophageal cancer. The correlation between various clinicopathological factors, including hematological markers of systemic inflammatory response, and survival or response to chemotherapy was examined. Among various hematological factors, leucocyte count, hemoglobin level, albumin level, neutrophil-lymphocyte ratio and CEA, but not serum concentration of C-reactive protein, were significantly associated with survival. Multivariate analysis revealed that the clinical response to chemotherapy, number of metastatic lymph nodes, operative complications and systemic inflammation score (SI score), comprising leucocyte count, albumin and hemoglobin levels, were independent prognostic factors, and identified the SI score as the most significant prognostic factor. There was no significant relationship between hematological markers of systemic inflammation, including the SI score, and the response to chemotherapy. In conclusion, in patients scheduled for chemotherapy followed by surgery for esophageal cancer, systemic inflammation, reflected by SI, predicts poor outcome, but not the response to chemotherapy.

View Figures

View References

1.	Muller JM, Erasmi H, Stelzner M, et al: Surgical therapy of oesophageal carcinoma. Br J Surg. 77:845–857. 1990. View Article : Google Scholar : PubMed/NCBI
2.	Refaely Y and Krasna MJ: Multimodality therapy for esophageal cancer. Surg Clin North Am. 82:729–746. 2002. View Article : Google Scholar : PubMed/NCBI
3.	Walsh TN, Noonan N, Hollywood D, et al: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 335:462–467. 1996. View Article : Google Scholar : PubMed/NCBI
4.	Gebski V, Burmeister B, Smithers BM, et al: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 8:226–234. 2007. View Article : Google Scholar : PubMed/NCBI
5.	Tepper J, Krasna MJ, Niedzwiecki D, et al: Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 26:1086–1092. 2008. View Article : Google Scholar
6.	Law S, Fok M, Chow S, et al: Pre-operative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg. 114:210–217. 1997. View Article : Google Scholar : PubMed/NCBI
7.	Medical Research Council Oesophageal Cancer Working Group: Surgical resection with or without pre-operative chemotherapy in oesophageal cancer: a randomized controlled trial. Lancet. 359:1727–1733. 2002. View Article : Google Scholar : PubMed/NCBI
8.	Yano M, Takachi K, Doki Y, et al: Pre-operative chemotherapy for clinically node-positive patients with squamous cell carcinoma of the esophagus. Dis Esophagus. 19:158–163. 2006. View Article : Google Scholar : PubMed/NCBI
9.	McMillan Dc, Canna K and McArdle CS: Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg. 90:215–219. 2003. View Article : Google Scholar
10.	Pierce BL, Ballard-Barbash R, Bernstein L, et al: Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 27:3437–3444. 2009. View Article : Google Scholar : PubMed/NCBI
11.	Kodama J, Miyagi Y, Seki N, et al: Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 82:107–110. 1999. View Article : Google Scholar : PubMed/NCBI
12.	Ishizuka M, Nagata H, Takagi K and Kubota K: Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer. Ann Surg. 250:268–272. 2009. View Article : Google Scholar
13.	Forrest LM, McMillan DC, McArdle CS, et al: A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer. 92:1834–1836. 2005. View Article : Google Scholar : PubMed/NCBI
14.	Al Murri AM, Bartlett JM, Canney PA, et al: Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer. 94:227–230. 2006.PubMed/NCBI
15.	Nozoe T, Saeki H and Sugimachi K: Significance of pre-operative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg. 182:197–201. 2001. View Article : Google Scholar : PubMed/NCBI
16.	Shimada H, Nabeya Y, Okazumi S, et al: Elevation of pre-operative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol. 83:248–252. 2003. View Article : Google Scholar : PubMed/NCBI
17.	Ikeda M, Natsugoe S, Ueno S, et al: Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma. Ann Surg. 238:197–202. 2003. View Article : Google Scholar : PubMed/NCBI
18.	Zingg U, Forberger J, Rajcic B, et al: Association of C-reactive protein levels and long-term survival after neoadjuvant therapy and esophagectomy for esophageal cancer. J Gastrointest Surg. 14:462–469. 2010. View Article : Google Scholar : PubMed/NCBI
19.	Miyata H, Yoshioka A, Yamasaki M, et al: Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy. Cancer. 115:3324–3334. 2009. View Article : Google Scholar
20.	Japanese Society for Esophageal Diseases: Guidelines for the Clinical and Pathologic Studies on Carcinoma of the Esophagus. 10th edition. Kanehara Syuppan; Tokyo: 2007
21.	Gomez D, Farid S, Malik HZ, et al: Pre-operative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg. 32:1757–1762. 2008. View Article : Google Scholar
22.	Walsh SR, Cook EJ, Goulder F, et al: Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 91:181–184. 2005. View Article : Google Scholar : PubMed/NCBI
23.	Macciò A, Madeddu C, Massa D, et al: Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. Blood. 106:362–367. 2005.
24.	Buck I, Morceau F, Grigorakaki C, et al: Linking anemia to inflammation and cancer: the crucial role of TNF alpha. Biochem Pharmacol. 77:1572–1579. 2009. View Article : Google Scholar : PubMed/NCBI
25.	Adamson JW: The anemia of inflammation/malignancy: mechanisms and management. Hematology Am Soc Hematol Educ Program. 2008:159–165. 2008. View Article : Google Scholar : PubMed/NCBI
26.	Gelin J, Moldawer LL, Lönnroth C, et al: Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res. 51:415–421. 1991.PubMed/NCBI
27.	Heikkilä K, Ebrahim S and Lawlor DA: A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health. 61:824–833. 2007.PubMed/NCBI
28.	Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
29.	McMillan DC, Watson WS, O'Gorman P, et al: Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer. 39:210–213. 2001. View Article : Google Scholar
30.	Argilés JM, Busquets S and López-Soriano FJ: Cytokines as mediators and targets for cancer cachexia. Cancer Treat Res. 130:199–217. 2006.
31.	Neal CP, Mann CD, Sutton CD, et al: Evaluation of the prognostic value of systemic inflammation and socioeconomic deprivation in patients with resectable colorectal liver metastases. Eur J Cancer. 45:56–64. 2009. View Article : Google Scholar : PubMed/NCBI
32.	Wang CY, Hsieh MJ, Chiu YC, et al: Higher serum C-reactive protein concentration and hypoalbuminemia are poor prognostic indicators in patients with esophageal cancer undergoing radiotherapy. Radiother Oncol. 92:270–275. 2009. View Article : Google Scholar : PubMed/NCBI
33.	Di Fiore F, Lecleire S, Pop D, et al: Baseline nutritional status is predictive of response to treatment and survival in patients treated by definitive chemoradiotherapy for a locally advanced esophageal cancer. Am J Gastroenterol. 102:2557–2563. 2007.PubMed/NCBI
34.	Crumley AB, McMillan DC, McKernan M, et al: Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer. 94:637–641. 2006.PubMed/NCBI
35.	Kobayashi T, Teruya M, Kishiki T, et al: Inflammation-based prognostic score, prior to neoadjuvant chemoradiotherapy, predicts postoperative outcome in patients with esophageal squamous cell carcinoma. Surgery. 144:729–735. 2008. View Article : Google Scholar
36.	DeNardo DG and Coussens LM: Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 9:2122007. View Article : Google Scholar
37.	Ulrich CM, Bigler J and Potter JD: Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer. 6:130–140. 2006. View Article : Google Scholar : PubMed/NCBI
38.	Macciò A, Lai P, Santona MC, et al: High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol. 69:248–252. 1998.PubMed/NCBI
39.	Canna K, McArdle PA, McMillan DC, et al: The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer. 92:651–654. 2005. View Article : Google Scholar
40.	Moyes LH, Leitch EF, McKee RF, et al: Pre-operative systemic inflammation predicts postoperative infectious complications in patients undergoing curative resection for colorectal cancer. Br J Cancer. 100:1236–1239. 2009. View Article : Google Scholar
41.	Lerut T, Moons J, Coosemans W, et al: Postoperative complications after transthoracic esophagectomy for cancer of the esophagus and gastroesophageal junction are correlated with early cancer recurrence: role of systematic grading of complications using the modified Clavien classification. Ann Surg. 250:798–807. 2009. View Article : Google Scholar
42.	Lagarde SM, de Boer JD, ten Kate FJ, et al: Postoperative complications after esophagectomy for adenocarcinoma of the esophagus are related to timing of death due to recurrence. Ann Surg. 247:71–76. 2008. View Article : Google Scholar : PubMed/NCBI